Rare Disease Drug Development Is Economically Nonviable for 95% of Known Rare Diseases

Of approximately 10,000 known rare diseases, only 5% have any treatment. Healthcare expenses for Americans with rare diseases are 3-5x greater than for those without. The total economic burden approaches $1 trillion annually. Small patient populations make traditional drug development ROI calculations impossible.

Traditional drug development costs $1.3-2.6B per approved drug. For a rare disease affecting 5,000 patients, even at $500K/year pricing, peak revenue cannot justify development costs. Natural history data is sparse, clinical trial design is hampered by small numbers and heterogeneous presentations. The FDA's Rare Pediatric Disease Priority Review Voucher program and Orphan Drug Act provide some incentives, but are insufficient for ultra-rare diseases (<1,000 patients). NCATS' Bespoke Gene Therapy Consortium (BGTC) aims to reduce gene therapy development costs for rare diseases.

Why It Matters

300M+ people worldwide have a rare disease. 50% of rare disease patients are children. 30% of children with rare diseases die before age 5. The $1T annual economic burden in the US alone makes this a massive societal problem.

Startup Approach

Build a platform that amortizes drug development costs across multiple rare diseases — e.g., a modular gene therapy platform where the vector and manufacturing are standardized and only the transgene cassette changes per disease. Or develop AI-powered drug repurposing platform to find existing approved drugs effective for rare diseases.

NIH Funding

NCATS 2025-2030 Strategic Plan prioritizes rare disease diagnosis and treatment. BGTC aims to create a standardized gene therapy development platform. NCATS budget supports TRND and RDoC (Rare Diseases Clinical Research Network).

Who's Working On It

NCATS Bespoke Gene Therapy Consortium (BGTC), Ultragenyx Pharmaceutical, BioMarin, Alexion/AstraZeneca, NCATS Therapeutics for Rare and Neglected Diseases (TRND)